Efficacy of Caffeine in ADCY5-Related Dyskinesia: A Retrospective Study
Méneret A, Mohammad SS, Cif L, Doummar D, DeGusmao C, Anheim M, Barth M, Damier P, Demonceau N, Friedman J, Gallea C, Gras D, Gurgel-Giannetti J, Innes EA, Necpál J, Riant F, Sagnes S, Sarret C, Seliverstov Y, Paramanandam V, Shetty K, Tranchant C, Doulazmi M, Vidailhet M, Pringsheim T, Roze E
Movement disorders : official journal of the Movement Disorder Society · 46 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cross-sectional study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2022-04-05 · Mov Disord · vol. 37 · issue 6 · pp. 1294–1298
- Publisher
- Wiley
- Cited
- 59 citations · more than 97% of similar papers · 5.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 16 works
- Access
- Paywalled
- Research areas
- Neurological disorders and treatments · Glycogen Storage Diseases and Myoclonus · Parkinson's Disease Mechanisms and Treatments
- Keywords
- Dyskinesia, Paroxysmal dyskinesia, Caffeine, Movement disorders, Retrospective cohort study, Disease, Medicine, Psychology, Psychiatry, Physical medicine and rehabilitation, Parkinson's disease, Internal medicine
- MeSH
- humans, movement disorders, dyskinesias, caffeine, retrospective studies, child, adenylyl cyclases
26 authors
From FR, AU, BR, BE, US, SK, RU, IN, CA
- Aurélie Méneret · correspondingCentre National de la Recherche Scientifique; Inserm; Sorbonne Université; Assistance Publique – Hôpitaux de Paris; Institut du Cerveau
- Shekeeb S. MohammadThe University of Sydney; Children's Hospital at Westmead
- Laura CifHôpital Gui de Chauliac
- Diane DoummarSorbonne Université
- Claudio DeGusmaoUniversidade Estadual de Campinas (UNICAMP)
- Mathieu AnheimCentre National de la Recherche Scientifique; Inserm; Institut de génétique et de biologie moléculaire et cellulaire; Hôpitaux Universitaires de Strasbourg; Université de Strasbourg
Abstract
Background
ADCY5-related dyskinesia is characterized by early-onset movement disorders. There is currently no validated treatment, but anecdotal clinical reports and biological hypotheses suggest efficacy of caffeine.
Objective
The aim is to obtain further insight into the efficacy and safety of caffeine in patients with ADCY5-related dyskinesia.
Methods
A retrospective study was conducted worldwide in 30 patients with a proven ADCY5 mutation who had tried or were taking caffeine for dyskinesia. Disease characteristics and treatment responses were assessed through a questionnaire.
Results
Caffeine was overall well tolerated, even in children, and 87% of patients reported a clear improvement. Caffeine reduced the frequency and duration of paroxysmal movement disorders but also improved baseline movement disorders and some other motor and nonmotor features, with consistent quality-of-life improvement. Three patients reported worsening.
Conclusion
Our findings suggest that caffeine should be considered as a first-line therapeutic option in ADCY5-related dyskinesia. © 2022 International Parkinson and Movement Disorder Society.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.